Results show that relugolix works well and is safe for patients with advanced prostate cancer in real-world use, whether taken alone or with other treatments.
In the first six months, patients maintained a stable quality of life, with no major decline reported in both single-drug and combination therapy groups. Most patients followed their treatment closely, with over 95% taking the medication at the correct time each day and about 83% never missing a dose. Serious side effects were uncommon, occurring in only 3.9% of patients, with anemia and heart attack reported in very small numbers. Only 6.1% of patients stopped treatment due to side effects.
The study followed nearly 1,000 patients across the United States, with an average age of about 71. Patients received relugolix either alone or combined with other therapies such as hormone-targeting drugs, chemotherapy, PARP inhibitors, immunotherapy, or radiation. The group included a wide range of disease stages, from localized prostate cancer to more advanced, treatment-resistant cases.